Please provide your email address to receive an email when new articles are posted on . Psoriasis patients who self-administer bimekizumab experienced similar levels of comfort and success with both ...
Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Secukinumab 300 mg administered with an auto-injector ...
SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ® ...
Xeris Pharmaceuticals last year snared approval for its first drug, a shelf-stable glucagon injector for hypoglycemia. Now it's deploying its formulation tech to hit another target—epilepsy—and the ...
Diabetes patients have long relied on complex glucagon kits to treat hypoglycemia. Late last summer, Xeris Pharmaceuticals aimed to change that with the first FDA-approved prefilled syringe. Now, its ...
Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- ...
ZURICH, June 28 (Reuters) - Idorsia (IDIA.S), opens new tab is launching a late-stage trial of its experimental heart-attack drug selatogrel that the Swiss company hopes will become what it describes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback